Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis

作者：Pourgholami Mohammad H^*; Khachigian Levon M; Fahmy Roger G; Badar Samina; Wang Lisa; Chu Stephanie Wai Ling; Morris David Lawson

来源：Biochemical and Biophysical Research Communications, 2010, 397(4): 729-734.

DOI：10.1016/j.bbrc.2010.06.019

• Angiogenesis inhibitor
• Albendazole
• Bevacizumab
• HUVEC
• VEGF
• VEGFR-2

The angiogenic process begins with the cell proliferation and migration into the primary vascular network, and leads to vascularization of previously avascular tissues and organs as well to growth and remodeling of the initially homogeneous capillary plexus to form a new microcirculation. Additionally, an increase in microvascular permeability is a crucial step in angiogenesis. Vascular endothelial growth factor (VEGF) plays a central role in angiogenesis. We have previously reported that albendazole suppresses VEGF levels and inhibits malignant ascites formation, suggesting a possible effect on angiogenesis. This study was therefore designed to investigate the antiangiogenic effect of albendazole in non-cancerous models of angiogenesis. In vitro, treatment of human umbilical vein endothelial cells (HUVECs) with albendazole led to inhibition of tube formation, migration, permeability and down-regulation of the VEGF type 2 receptor (VEGFR-2). In vivo albendazole profoundly inhibited hyperoxia-induced retinal angiogenesis in mice. These results provide new insights into the antiangiogenic effects of albendazole.

• 出版日期2010-7-9